Davide Melisi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4326106/publications.pdf

Version: 2024-02-01

180	6,552	87723 38	76769 74
papers	citations	h-index	g-index

185	185	185	9291
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 671-684.	5.1	923
2	Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2004, 10, 784-793.	3.2	337
3	LY2109761, a novel transforming growth factor Î² receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics, 2008, 7, 829-840.	1.9	285
4	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. British Journal of Cancer, 2018, 119, 1208-1214.	2.9	195
5	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget, 2014, 5, 2839-2852.	0.8	171
6	Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer Discovery, 2021, 11, 326-339.	7.7	144
7	Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. International Journal of Molecular Sciences, 2018, 19, 431.	1.8	142
8	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Antiâ€“Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 5069-5080.	3.2	139
9	Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. Journal of the National Cancer Institute, 2011, 103, 1190-1204.	3.0	137
10	Key cancer cell signal transduction pathways as therapeutic targets. European Journal of Cancer, 2006, 42, 290-294.	1.3	131
11	EMT and Treatment Resistance in Pancreatic Cancer. Cancers, 2017, 9, 122.	1.7	105
12	Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical Cancer Research, 2003, 9, 1566-72.	3.2	104
13	Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 932.	2.2	97
14	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. Journal of Translational Medicine, 2018, 16, 219.	1.8	96
15	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFGFR2rearrangements. Future Oncology, 2020, 16, 2385-2399.	1.1	96
16	Safety and activity of the TGFÎ² receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. , 2021, 9, e002068.		95
17	HER2 loss in HER2â€positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. International Journal of Cancer, 2016, 139, 2859-2864.	2.3	94
18	NF-ÎºB as a target for cancer therapy. Expert Opinion on Therapeutic Targets, 2007, 11, 133-144.	1.5	91

#	Article	IF	Citations
19	IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-ÎºB Activation. Clinical Cancer Research, 2016, 22, 1432-1444.	3.2	90
20	Anti-VEGF Treatmentâ€“Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype. Clinical Cancer Research, 2011, 17, 5822-5832.	3.2	86
21	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. Clinical Cancer Research, 2005, 11, 5639-5644.	3.2	83
22	NF-ÎºB as a target for pancreatic cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, S1-S10.	1.5	81
23	Secreted Interleukin-1Î± Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of Nuclear Factor-ÎºB. Molecular Cancer Research, 2009, 7, 624-633.	1.5	80
24	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Frontiers in Pharmacology, 2013, 4, 56.	1.6	79
25	Angiogenesis: A Target for Cancer Therapy. Current Pharmaceutical Design, 2004, 10, 11-26.	0.9	72
26	An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. Clinical Cancer Research, 2016, 22, 6164-6175.	3.2	65
27	Gastric cancer: Translating novels concepts into clinical practice. Cancer Treatment Reviews, 2019, 79, 101889.	3.4	60
28	TGFÎ² receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 975-991.	1.1	60
29	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. World Journal of Gastroenterology, 2015, 21, 4788.	1.4	56
30	KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. Journal of Experimental and Clinical Cancer Research, 2020, 39, 227.	3.5	49
31	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 1183-1196.	1.5	48
32	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research, 2011, 17, 6531-6541.	3.2	47
33	An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget, 2015, 6, 13822-13834.	0.8	47
34	Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	5.8	45
35	The Pan-Immune-Inflammation Value in microsatellite instabilityâ€“high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 150, 155-167.	1.3	45
36	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45

#	Article	IF	Citations
37	Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. International Journal of Oncology, 2015, 46, 1099-1108.	1.4	44
38	Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. Blood, 2020, 135, 2071-2084.	0.6	44
39	Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Pancreatology, 2018, 18, 420-428.	0.5	43
40	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open, 2020, 5, e000587.	2.0	43
41	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	1.9	42
42	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology, 2021, 11, 638360.	1.3	42
43	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research, 2017, 23, 4312-4322.	3.2	41
44	TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. British Journal of Cancer, 2015, 113, 878-885.	2.9	40
45	Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity. Clinical Cancer Research, 2009, 15, 6367-6377.	3.2	39
46	A circulating T_H2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. OncoImmunology, 2017, 6, e1322242.	2.1	39
47	Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. Hpb, 2019, 21, 596-603.	0.1	39
48	Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. International Journal of Molecular Sciences, 2018, 19, 3331.	1.8	38
49	Noncoding RNA in Cholangiocarcinoma. Seminars in Liver Disease, 2019, 39, 013-025.	1.8	38
50	Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clinical Cancer Research, 2001, 7, 4156-63.	3.2	38
51	Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?. ESMO Open, 2017, 2, e000206.	2.0	37
52	Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Molecular Cancer Therapeutics, 2020, 19, 247-257.	1.9	37
53	TAK -ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. Drug Resistance Updates, 2017, 33-35, 36-42.	6.5	36
54	Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. European Journal of Cancer, 2019, 106, 24-33.	1.3	36

#	Article	IF	Citations
55	CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. Anticancer Research, 2018, 38, 4889-4895.	0.5	34
56	Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis. Antioxidants and Redox Signaling, 2018, 28, 1-14.	2.5	33
57	Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease. Current Pharmaceutical Design, 2014, 20, 6660-6669.	0.9	33
58	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	2.7	32
59	Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.. Endocrine-Related Cancer, 2004, 11, 51-68.	1.6	31
60	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocrine-Related Cancer, 2005, 12, 1051-1058.	1.6	31
61	Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines, 2014, 2, 211-228.	1.4	31
62	Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International Journal of Obesity, 2018, 42, 334-343.	1.6	31
63	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opinion on Drug Safety, 2014, 13, 535-549.	1.0	30
64	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	3.6	30
65	Rationale and clinical use of multitargeting anticancer agents. Current Opinion in Pharmacology, 2013, 13, 536-542.	1.7	29
66	Combined inhibition of IL1, CXCR1/2, and TGFÎ² signaling pathways modulates in-vivo resistance to anti-VEGF treatment. Anti-Cancer Drugs, 2016, 27, 29-40.	0.7	29
67	A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).. Journal of Clinical Oncology, 2016, 34, 4019-4019.	0.8	29
68	Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. Free Radical Biology and Medicine, 2017, 112, 376-386.	1.3	28
69	Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. European Journal of Clinical Nutrition, 2018, 72, 772-779.	1.3	28
70	A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophagealâ€“gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093788.	1.4	28
71	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	1.9	27
72	Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncology, 2021, 17, 389-402.	1.1	27

#	Article	IF	Citations
73	First-In-Human Phase I Study of a Next-Generation, Oral, TGFÎ² Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 2021, 27, 6666-6676.	3.2	27
74	MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. Anticancer Research, 2018, 38, 1937-1946.	0.5	27
75	Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Molecular Cancer Therapeutics, 2004, 3, 977-83.	1.9	27
76	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	2.0	26
77	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British Journal of Cancer, 2017, 116, 1247-1253.	2.9	25
78	Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis. Case Reports in Oncology, 2018, 11, 615-621.	0.3	25
79	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) Î² receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 4124-4124.	0.8	24
80	From Genetic Alterations to Tumor Microenvironment: The Ariadneâ€™s String in Pancreatic Cancer. Cells, 2020, 9, 309.	1.8	23
81	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. European Journal of Cancer, 2019, 117, 84-90.	1.3	21
82	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 5325-5334.	0.7	20
83	Organisational challenges, volumes of oncological activityÂand patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. European Journal of Cancer, 2020, 135, 159-169.	1.3	20
84	Permissive State of EMT: The Role of Immune Cell Compartment. Frontiers in Oncology, 2020, 10, 587.	1.3	19
85	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open, 2021, 6, 100032.	2.0	19
86	NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. Critical Reviews in Oncology/Hematology, 2019, 144, 102826.	2.0	18
87	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4661-4669.	3.2	18
88	The Multifaceted Role of TGF-Î² in Gastrointestinal Tumors. Cancers, 2021, 13, 3960.	1.7	18
89	The curious case of GÎ±s gain-of-function in neoplasia. BMC Cancer, 2018, 18, 293.	1.1	17
90	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16

#	Article	IF	Citations
91	The development of PARP as a successful target for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 161-175.	1.1	16
92	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers, 2020, 12, 1022.	1.7	16
93	Radiation detectors based on Multiwall Carbon Nanotubes deposited by a spray technique. Thin Solid Films, 2013, 543, 19-22.	0.8	15
94	Population pharmacokinetics and exposureâ€“overall survival analysis of the transforming growth factor-Î² inhibitor galunisertib in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 1003-1015.	1.1	15
95	Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open, 2022, 7, 100505.	2.0	15
96	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. Cancers, 2020, 12, 3299.	1.7	14
97	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. Oncologist, 2020, 25, 780-786.	1.9	14
98	Current Strategies to Overcome Resistance to ALK-Inhibitor Agents. Current Drug Metabolism, 2015, 16, 585-596.	0.7	13
99	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRASâ€“Dependent Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 5612-5625.	0.4	11
100	Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. Abdominal Radiology, 2020, 45, 3809-3818.	1.0	11
101	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. Journal of Gastric Cancer, 2019, 19, 375.	0.9	11
102	Editorial [Hot Topic: Pancreatic Cancer: Between Bench and Bedside (Guest Editors: Davide Melisi and) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	10
103	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. Future Oncology, 2017, 13, 2265-2275.	1.1	10
104	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 2019, 45, 1479-1482.	0.5	10
105	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines, 2020, 8, 191.	2.1	10
106	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
107	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A â€œreal-lifeâ€•study.. Journal of Clinical Oncology, 2015, 33, 424-424.	0.8	10
108	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094796.	1.4	9

#	Article	IF	Citations
109	Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma. Hepatology, 2021, 74, 3235-3248.	3.6	9
110	Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC). , 2016, , .		9
111	Micro-RNA in Cholangiocarcinoma: Implications for Diagnosis, Prognosis, and Therapy. Journal of Molecular Pathology, 2022, 3, 88-103.	0.5	9
112	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. Frontiers in Cell and Developmental Biology, 2020, 8, 308.	1.8	8
113	Spray deposited carbon nanotubes for organic vapor sensors. Microelectronics Journal, 2014, 45, 1691-1694.	1.1	7
114	Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Oncology and Therapy, 2021, 9, 557-573.	1.0	7
115	Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. Pancreatology, 2021, 21, 1038-1047.	0.5	7
116	The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting. Cancer Management and Research, 2021, Volume 13, 7747-7757.	0.9	7
117	Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. Expert Review of Molecular Diagnostics, 2018, 18, 357-370.	1.5	6
118	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Journal of Geriatric Oncology, 2019, 10, 591-597.	0.5	6
119	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers, 2020, 12, 1131.	1.7	6
120	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989028.	1.4	6
121	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Current Drug Targets, 2021, 22, 1021-1033.	1.0	6
122	2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts). European Journal of Cancer, 2015, 51, S445.	1.3	5
123	Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. Journal of Physical Education and Sports Management, 2016, 2, a000620.	0.5	5
124	Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. Journal of Clinical Oncology, 2016, 34, 4124-4124.	0.8	5
125	Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.. Journal of Clinical Oncology, 2019, 37, TPS462-TPS462.	0.8	5
126	Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Future Oncology, 2021, 17, 1843-1854.	1.1	4

#	Article	IF	Citations
127	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. Journal of Clinical Oncology, 2015, 33, 412-412.	0.8	4
128	Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion. JCO Precision Oncology, 2022, 6, e2100400.	1.5	4
129	Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-Î² receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, TPS501-TPS501.	0.8	3
130	Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.. Journal of Clinical Oncology, 2020, 38, 660-660.	0.8	3
131	Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert Review of Gastroenterology and Hepatology, 2022, 16, 73-79.	1.4	3
132	Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Frontiers in Surgery, 2022, 9, .	0.6	3
133	242P Effects of nal-IRI (MM-398) Â± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1. Annals of Oncology, 2016, 27, .	0.6	2
134	Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A â€œREAL LIFEâ€•study.. Journal of Clinical Oncology, 2017, 35, 396-396.	0.8	2
135	Clinical Impact of Folfirinox Dose/Schedule Modifications (Mfolforinox) and Additional Supportive Measures in the Management of Pancreatic Cancer (Pdac) Patients (Pts). Annals of Oncology, 2014, 25, iv234.	0.6	1
136	2334 Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian â€œreal lifeâ€•study. European Journal of Cancer, 2015, 51, S444.	1.3	1
137	O-004 Effects of nal-IRI (MM-398)ÂÂ±Â5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine. Annals of Oncology, 2016, 27, ii119.	0.6	1
138	First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe. Annals of Oncology, 2018, 29, viii244-viii245.	0.6	1
139	Symptoms at diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine practice and frequency variation across Europe. Annals of Oncology, 2018, 29, ix61-ix62.	0.6	1
140	Resistance to ALK Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 147-163.	0.1	1
141	Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice.. Journal of Clinical Oncology, 2012, 30, e14661-e14661.	0.8	1
142	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. Journal of Clinical Oncology, 2020, 38, e16769-e16769.	0.8	1
143	Biliary tract cancer (BTC) in the elderly: A real-world tertiary cancer center experience.. Journal of Clinical Oncology, 2020, 38, 492-492.	0.8	1
144	Activity of nab-paclitaxel (nab-P) monotherapy in heavily pretreated pancreatic cancer (aPDAC) patients (pts): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2013, 31, e15057-e15057.	0.8	1

#	Article	IF	Citations
145	Abstract 3339: Modulating TAK1 expression through the inhibition of GSK3 impairs YAP/TAZ oncogenic functions in pancreatic cancer. , 2018, , .		1
146	A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements. Blood, 2021, 138, 3656-3656.	0.6	1
147	The Last Dance for Chemotherapy Intensification in Non-Asian Advanced Biliary Tract Cancers?. Journal of Clinical Oncology, 2022, , JCO2102509.	0.8	1
148	Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.. Journal of Clinical Oncology, 2022, 40, e16256-e16256.	0.8	1
149	2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy. European Journal of Cancer, 2015, 51, S454-S455.	1.3	0
150	248 Fibroblast Growth Factor Receptor (FGFR)3 sustains acquired resistance to trastuzumab in gastric cancer patients. European Journal of Cancer, 2015, 51, S42-S43.	1.3	0
151	Effects of nanoliposomal irinotecan (nal-IRI; MM-398) Â± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study. Annals of Oncology, 2016, 27, iv18.	0.6	0
152	Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. Data in Brief, 2017, 15, 376-381.	0.5	0
153	A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Annals of Oncology, 2017, 28, v27.	0.6	0
154	Prognostic impact of nutritional support in patients affected by locally advanced or metastatic pancreatic cancer (PC) undergone chemotherapy. Annals of Oncology, 2017, 28, vi47.	0.6	0
155	Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.. Annals of Oncology, 2017, 28, iii43-iii44.	0.6	0
156	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Annals of Oncology, 2017, 28, vi45.	0.6	0
157	Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system. Journal of Gastrointestinal Oncology, 2017, 8, 187-188.	0.6	0
158	Symptoms reported at initial diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice and variation in frequencies across Europe. Annals of Oncology, 2018, 29, v47.	0.6	0
159	Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe. Annals of Oncology, 2018, 29, v100-v101.	0.6	0
160	Prognostic role of early nutritional support in patients affected by advanced pancreatic cancer undergoing chemotherapy. Nutrition, 2018, 50, e2.	1.1	0
161	A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1151-1152.	2.3	0
162	Target Therapy and Immunotherapy in Gastric Cancer. Updates in Surgery Series, 2021, , 225-233.	0.0	0

#	Article	IF	Citations
163	A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. Journal of Clinical Oncology, 2005, 23, 3191-3191.	0.8	0
164	Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT. , 2011, , .		0
165	FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. Journal of Clinical Oncology, 2015, 33, 372-372.	0.8	0
166	Abstract 579: TAK1-regulated expression of BIRC3 is responsible for chemoradiotherapy (CRT) resistance in esophagogastric junction (EGJ) adenocarcinoma. , 2015, , .		0
167	Abstract 3605: Combined inhibition of IL-1, CXCR1/2, and TGFÎ² signaling pathways modulates in vivo acquired resistance to anti-VEGF treatment. , 2015, , .		0
168	Abstract 26: Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001. , 2016, , .		0
169	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI;) Tj ETQq1 1 0.784314 rgBT /Over adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.. Journal of Clinical Oncology, 2016, 34, e15732-e15732.	0.8	0
170	Abstract 2046: Exposure - response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in a randomized phase 2, double-blind study. , 2016, , .		0
171	Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors. , 2016, , .		0
172	242P Effects of nal-IRI (MM-398) 6 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1. Annals of Oncology, 2016, 27, ix76.	0.6	0
173	Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma. , 2017, , 85-94.		0
174	Abstract 3501: Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. , 2018, , .		0
175	Abstract 973: MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity. , 2018, , .		0
176	Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status. , 2019, , .		0
177	The Vasculopathy in the Bone Marrow Microenvironment of Humanized Sickle Cell Mice Is Reversible By Blood Transfusion. Blood, 2019, 134, 2256-2256.	0.6	0
178	The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial.. Journal of Clinical Oncology, 2020, 38, e18508-e18508.	0.8	0
179	A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS4664-TPS4664.	0.8	0
180	176: YAP/TAZ ACTIVATION IS A MECHANISM OF TUMOR PROGRESSION IN THE POORLY COHESIVE GASTRIC CANCER PHENOTYPE. Ecological Management and Restoration, 2022, 35, .	0.2	0